CI vs SPRY · P/E 2.4, rev $274.90B vs rev $89.1M
Cigna Corp (CI) versus ARS Pharmaceuticals, Inc (SPRY) — a side-by-side from cached financials, not a winner call.
Cigna Corp (CI) is a healthcare plans company listed on US.
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
Latest reported CI revenue for 2025-12-31 was $274.90B. Net income was $5.96B. Revenue was up 11.2% from 2024-12-31 to 2025-12-31. CI currently screens at market cap $71.62B and trailing P/E 2.4.
Latest reported SPRY revenue for 2024-12-31 was $89.1M. Net income was $8.0M. Revenue was up 297063.3% from 2023-12-31 to 2024-12-31. SPRY currently screens at market cap $983.1M.
CI currently screens at market cap $71.62B and trailing P/E 2.4. SPRY currently screens at market cap $983.1M.
Not investment advice. Open the CI and SPRY stock pages for the full models.
Not investment advice.